Latest 10-K annual reports

MVB Financial Corp. reported a significant increase in net income for 2025, driven by strategic divestitures and improved efficiency, despite a slight decline in net interest income.

DUKE Robotics Corp. reported increased revenues from its IC Drone services and initial royalties from defense systems in 2025, despite ongoing net losses and a going concern warning.

HeartBeam, Inc. reports significant progress in its 3D ECG technology with recent FDA clearances and initiates a limited market launch, despite ongoing concerns about its ability to continue as a going concern.

Eventbrite, the global live events marketplace, has been acquired by Bending Spoons for $4.50 per share in cash, ceasing to be a publicly traded company.

Kingsway Financial Services Inc. reports a net loss of $10.25 million in 2025, driven by increased operating expenses and acquisitions, while strategically expanding its Kingsway Search Xcelerator segment.

Inovio Pharmaceuticals reports a $84.9 million net loss for 2025 and faces substantial doubt about its ability to continue as a going concern, while its lead RRP candidate, INO-3107, encounters FDA questions on accelerated approval eligibility.

Filana Therapeutics, formerly Cassava Sciences, has discontinued its Alzheimer's program, pivoted to TSC-related epilepsy, and faces a clinical hold on its lead candidate, simufilam, while settling significant legal claims.

PAMT Corp reported a significant net loss of $52.6 million for fiscal year 2025, driven by declining revenues across its truckload and brokerage segments and a substantial increase in insurance and claims expenses.

Nephros, Inc. announced a significant increase in net income and revenue for fiscal year 2025, driven by higher programmatic sales and emergency response business, despite ongoing tariff impacts and an identified material weakness in internal controls.

Heritage Global Inc. reports a decline in net income and operating income for 2025, driven by a shift in revenue mix and significant nonaccrual loans in its Specialty Lending segment.

Zumiez Inc. reported a return to profitability in fiscal year 2025 with diluted earnings per share of $0.78, driven by a 4.5% increase in net sales and significant product margin improvements.

MainStreet Bancshares, Inc. reported a significant net loss for fiscal year 2024, primarily driven by a $19.7 million impairment charge related to its Avenu financial technology software.

Rare Element Resources details progress on its rare earth Demonstration Plant and Bear Lodge project permitting, alongside a recent $30.9M capital raise, in its 2025 annual report.

Ameriprise Financial, Inc. filed an amendment to its annual report on Form 10-K solely to correct a typographical error regarding the as-of date for the effectiveness of internal control over financial reporting.

VanEck Bitcoin ETF saw its Net Asset Value increase by 7.95% in 2025, despite a 6.34% decline in Bitcoin's price, driven by significant share creations.

Income Opportunity Realty Investors, Inc. reported a decrease in net income and earnings per share for the fiscal year ended December 31, 2025, primarily due to lower interest income from related parties.

Transcontinental Realty Investors, Inc. reported a significant increase in net income for fiscal year 2025, driven by substantial gains from property dispositions and growth in its commercial segment, despite a decrease in multifamily NOI.

American Realty Investors, Inc. reported a significant swing to net income in 2025, driven by substantial gains from property dispositions and the favorable resolution of long-standing litigation.

Heritage Insurance Holdings, Inc. reported a significant financial turnaround in 2025, with net income increasing by 217.8% to $195.6 million, driven by improved underwriting and lower catastrophe losses.

VitaSpring Biomedical Co. Ltd. reported no revenue for fiscal year 2024, a net loss of $1.1 million, and a substantial accumulated deficit, raising significant doubt about its ability to continue as a going concern.

CF Bankshares Inc. reported a 31% increase in net income for 2025, driven by higher net interest income and improved efficiency, despite increased credit loss provisions.

First US Bancshares, Inc. reported a significant decrease in net income and earnings per share for fiscal year 2025, primarily driven by a substantial increase in provision for credit losses, despite growth in total assets and deposits.

Seres Therapeutics, Inc. reports a strategic pivot towards inflammatory and immune diseases, pausing further investment in its lead infectious disease candidate SER-155's Phase 2 study due to funding needs, while detailing 2025 financial results including a net income from continuing operations.

reAlpha Tech Corp. reported a significant increase in revenue and a reduction in net loss from continuing operations for the fiscal year ended December 31, 2025, driven by its homebuying and technology services segments.

Candel Therapeutics reports positive Phase 3 prostate cancer data, secures $100M royalty deal, and plans pivotal trials for lung cancer, extending its financial runway into Q1 2028.

Theriva Biologics announced positive Phase 2b pancreatic cancer trial results for VCN-01 and a strategic shift to focus on oncology, while licensing out its SYN-020 asset.

Astrana Health's 2025 annual report highlights significant revenue and Adjusted EBITDA growth driven by strategic acquisitions, despite a decline in net income and an identified material weakness in internal controls.

MBX Biosciences, Inc. reported significant progress in its clinical pipeline, including positive Phase 2 results for canvuparatide in hypoparathyroidism and advancement of obesity and post-bariatric hypoglycemia candidates, alongside increased net losses and a strong cash position to fund operations into 2029.

Century Therapeutics reported a significant reduction in net loss for 2025, driven by collaboration revenue, and extended its cash runway into Q1 2029 with a recent private placement, while reprioritizing its cell therapy pipeline.

Orchestra BioMed Holdings, Inc. reported a net loss of $52.7 million for 2025, while advancing key clinical trials for its AVIM Therapy and Virtue SAB product candidates and securing new financing.